SLC5A2 and diabetes mellitus: First, diabetes therapies, including SGLT2 inhibitors, receive some of the largest manufacturer discounts observed in the US pharmaceutical market, and these discounts have fully offset increases in list prices in recent years.7 Second, the availability of several SGLT2 inhibitors with proven benefit in HFrEF treatment may allow payers to negotiate better prices in return for preferential formulary placement.5,47 As a result, the majority of US payers will be able to continue to access at least 1 SGLT2 inhibitor at a reasonable price.